Abstract
Osteoporosis is very common in elderly patients. Despite the severe health-related consequences for individual patients and the socioeconomic costs caused by osteoporotic fractures, treatment rates are still low. Due to drug interactions and patient compliance, polypharmacy is often mentioned as a reason for undertreatment. Several drugs have a direct or indirect effect on bone metabolism. The present paper discusses the risk of interactions of anti-osteoporotic drugs (oral and parenteral bisphosphonates, raloxifene, strontium ranelate, teriparatide, and denosumab) with other common medications in elderly patients and their impact on bone metabolism and fracture risk. In summary, the number and risk of drug interactions of all common anti-osteoporotic drugs are small and clinically rather irrelevant. However, patients with a polypharmacy are at a higher risk of fractures and should receive osteoporosis treatment, if indicated.
Zusammenfassung
Osteoporose hat eine hohe Prävalenz bei älteren Patienten. Trotz der enormen individuellen Folgen für die Betroffenen und die hohen sozioökonomischen Kosten osteoporotischer Frakturen sind die Therapieraten weiterhin sehr gering. Als Begründung wird immer wieder die Polypharmazie genannt, insbesondere im Hinblick auf mögliche Medikamenteninteraktionen sowie die Compliance. Zahlreiche Medikamente haben einen direkten oder indirekten Einfluss auf den Knochenmetabolismus. Im vorliegenden Review wird die Bedeutung möglicher Interaktionen diskutiert sowie das Frakturrisiko im Rahmen einer Polypharmazie dargestellt. Einerseits zeigt sich, dass das Interaktionspotenzial der zugelassenen Osteoporosemedikamente gering ist. Andererseits haben Patienten mit einer Polypharmazie ein erhöhtes Frakturrisiko und sollten eine Osteoporosetherapie erhalten, wenn diese indiziert ist.
Similar content being viewed by others
References
Leung F, Blauth M, Bavonratanavech S (2010) Surgery for fracture—streamlining the process. Osteoporos Int 21(Suppl 4):519–552
Bartl R (2008) Osteoporose – Prävention – Diagnostik – Therapie. Georg Thieme, Stuttgart-New York, pp 1–2
Becker C, Gebhard F, Muche R et al (1999) Epidemiologie der Stürze Älterer. Z Orthop 137:482–485
Häussler B, Gothe H, Göl D et al (2007) Epidemiology, treatment and costs of osteoporosis in Germany-the BoneEVA Study. Osteoporos Int 18:77–84
Kammerlander C, Gosch M, Kammerlander-Knauer U et al (2011) Long-term functional outcome in geriatric hip fracture patients. Arch Orthop Trauma Surg 131:1435–1444
Jennings LA, Auerbach AD, Maselli J et al (2010) Missed opportunities for osteoporosis treatment in patients hospitalized for hip fracture. J Am Geriatr Soc 58:650–657
Kuijpers MA, Marum RJ van, Egberts AC et al (2008) Relationship between polypharmacy and underprescribing. Br J Clin Pharmacol 65:130–133
Gosch M, Roth T, Kammerlander C et al (2011) Treatment of osteoporosis in postmenopausal hip fracture patients after geriatric rehabilitation: changes over the last decade. Z Gerontol Geriatr 44:381–386
Solomon DH, Brookhart MA, Tsao P et al (2011) Predictors of very low adherence with medications for osteoporosis: towards development of a clinical prediction rule. Osteoporos Int 22:1737–1743
Kirigaya D, Nakayama T, Ishizaki T et al (2011) Management and treatment of osteoporosis in patients receiving long-term glucocorticoid treatment: current status of adeherence to clinical guidelines and related factors. Intern Med 50:2793–2800
Reid IR, Heap SW (1990) Determinants of vertebral mineral density in patients receiving long-term glucocorticoid therapy. Arch Intern Med 150:2545–2548
Van Staa TP, Leufkens HG, Cooper C (2002) The epidemiology of cortisteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 13:777–787
Rejnmark L, Vestergaard P, Heickendorff L et al (2006) Loop diuretics increase bone turnover and decrease BMD in osteopenic postmenopausal women: results from a randomized controlled study with bumetanide. J Bone Miner Res 21:163–170
Heidrich FE, Stergachis A, Gross KM (1991) Diuretic drug use and the risk for hip fracture. Ann Intern Med 115:1–6
Lim LS, Fink HA, Blackwell T et al (2009) Loop diuretic use and rates of hip bone loss and risk of falls and fractures in older women. J Am Geriatr Soc 57:855–862
Verdel BM, Souverein PC, Egberts TC et al (2010) Use of antidepressant drugs and risk of osteoporotic and non-osteoporotic fractures. Bone 47:604–609
Haney EM, Chan BK, Diem SJ et al (2007) Association of low bone mineral density with selective serotonin reuptake inhibitor use by older men. Arch Intern Med 167:1246–1251
Richards JB, Papaioannou A, Adachi JD et al (2007) Effect of selective serotonin reuptake inhibitors on the risk of fracture. Arch Intern Med 167:188–194
Haney EM, Warden SJ, Bliziotes MM (2010) Effects of selective serotonin reuptake inhibitors on bone health in adults: time for recommendations about screening, prevention and management? Bone 46:13–17
Gajic-Veljanoski O, Bayoumi AM, Tomlinson G et al (2012) Vitamin K supplementation for the primary prevention of osteoporotic fractures: is it cost-effective and is future research warranted? Osteoporos Int (Epub ahead of print)
Philip WJ, Martin JC, Richardson JM et al (1995) Decreased axial and peripheral bone density in patients taking long-term warfarin. QJM 88:635–640
Gage BF, Birman-Deych E, Radford MJ et al (2006) Risk of osteoporotic fracture in elderly patients taking warfarin: results from the National Registry of Atrial Fibrillation 2. Arch Intern Med 166:241–246
Barbour LA, Kick SD, Steiner JF et al (1994) A prospective study of heparin-induced osteoporosis in pregnancy using bone densitometry. Am J Obstet Gynecol 170:862–869
Dahlman TC (1993) Osteoporotic fractures and the recurrence of thromboembolism during pregnancy and the puerperium in 184 women undergoing thromboprophylaxis with heparin. Am J Obstet Gynecol 168:1265–1270
Pettilä V, Leinonen P, Markkola A et al (2002) Postpartum bone mineral density in women treated for thromboprophylaxis with unfractionated heparin or LMW heparin. Thromb Haemost 87:182–186
Ross FP (2006) M-CSF, c-Fms, and signaling in osteoclasts and their precursors. Ann N Y Acad Sci 1068:110–116
Leese GP, Jung RT, Guthrie C et al (1992) Morbidity in patients on L-thyroxine: a comparison of those with a normal TSH to those with a suppressed TSH. Clin Endocrinol (Oxf) 37:500–503
Faber J, Galløe AM (1994) Changes in bone mass during prolonged subclinical hyperthyroidism due to L-thyroxine treatment: a meta-analysis. Eur J Endocrinol 130:350–356
O’Connell MB, Madden DM, Murray AM et al (2005) Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial. Am J Med 118:778–781
Serfaty-Lacrosniere C, Wood RJ, Voytko D et al (1995) Hypochlorhydria from short-term omeprazole treatment does not inhibit intestinal absorption of calcium, phosphorus, magnesium or zinc from food in humans. J Am Coll Nutr 14:364–368
Yang YX, Lewis JD, Epstein S, Metz DC (2006) Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 296:2947–2953
Laine L (2009) Proton pump inhibitors and bone fractures? Am J Gastroenterol 104(Suppl 2):21–26
Gray SL, LaCroix AZ, Larson J et al (2010). Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women’s Health Initiative. Arch Intern Med 170:765–771
Zaidi M (1990) Modularity of osteoclast behaviour and “mode-specific” inhibition of osteoclast function. Biosci Rep 10:547–556
Heikkinen S, Auwerx J, Argmann CA (2007) PPARgamma in human and mouse physiology. Biochim Biophys Acta 1771:999–1013
Grey A (2008) Skeletal consequences of thiazolidinedione therapy. Osteoporos Int 19:129–137
Kahn SE, Zinman B, Lachin JM et al (2008) Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care 31:845–851
Motola D, Piccinni C, Biagi C et al (2012) Cardiovascular, ocular and bone adverse reactions associated with thiazolidinediones: a disproportionality analysis of the US FDA adverse event reporting system database. Drug Saf 35:315–323
Meier C, Kraenzlin ME, Bodmer M et al (2008) Use of thiazolidinediones and fracture risk. Arch Intern Med 168:820–825
Eastell R, Hannon RA, Cuzick J et al (2006) Effect of an aromatase inhibitor on bmd and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230). J Bone Miner Res 21:1215–1223
Howell A (2005) Adjuvant aromatase inhibitors for breast cancer. Lancet 366:431–433
Bartl R, Bartl C, Gradinger R (2009) Drug-induced osteopathies. Drugs, pathogenesis, forms, diagnosis, prevention and therapy. Orthopade 38:1245–1260
Vestergaard P, Hermann P, Jensen JE et al (2012) Effects of paracetamol, non-steroidal anti-inflammatory drugs, acetylsalicylic acid, and opioids on bone mineral density and risk of fracture: results of the Danish Osteoporosis Prevention Study (DOPS). Osteoporos Int 23:1255–1265
Gosch M (2003) Are statins of value in therapy of osteoporosis? Wien Med Wochenschr 153:255–257
LaCroix AZ, Cauley JA, Pettinger M et al (2003) Statin use, clinical fracture, and bone density in postmenopausal women: results from the Women’s Health Initiative Observational Study. Ann Intern Med 139:97–104
LaCroix AZ, Ott SM, Ichikawa L et al (2000) Low-dose hydrochlorothiazide and preservation of bone mineral density in older adults. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 133:516–526
Graham S, Hammond-Jones D, Gamie Z et al (2008) The effect of beta-blockers on bone metabolism as potential drugs under investigation for osteoporosis and fracture healing. Expert Opin Investig Drugs 17:1281–1299
Togari A, Arai M, Kondo A (2005) The role of the sympathetic nervous system in controlling bone metabolism. Expert Opin Ther Targets 9:931–940
Pasco JA, Henry MJ, Sanders KM et al (2004) Beta-adrenergic blockers reduce the risk of fracture partly by increasing bone mineral density: Geelong Osteoporosis Study. J Bone Miner Res 19:19–24
Laroche ML, Charmes JP, Nouaille Y et al (2007) Is inappropriate medication use a major cause of adverse drug reactions in the elderly? Br J Clin Pharmacol 63:177–186
Mannesse CK, Derkx FH, Ridder MA de et al (2000) Contribution of adverse drug reactions to hospital admission of older patients. Age Ageing 29:35–39
Woolcott JC, Richardson KJ, Wiens MO et al (2009) Meta-analysis of the impact of 9 medication classes on falls in elderly persons. Arch Intern Med 169:1952–1960. (Review. Erratum in: Arch Intern Med 2010 170:477)
Conflict of interest
On behalf of all authors, the corresponding author states that there are no conflicts of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Gosch, M., Jeske, M., Kammerlander, C. et al. Osteoporosis and polypharmacy. Z Gerontol Geriat 45, 450–454 (2012). https://doi.org/10.1007/s00391-012-0374-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00391-012-0374-7